Neoadjuvant Therapy for Stage IIIA HER2-Positive Breast Cancer

Standard Neoadjuvant Regimen Components

The American Society of Clinical Oncology and European Society for Medical Oncology recommend trastuzumab plus pertuzumab as the required standard for Stage II-III HER2-positive disease, achieving significantly higher pathological complete response rates compared to trastuzumab alone (45.8% vs 29%) and translating into improved long-term outcomes, particularly in node-positive cancers 1, 2, 3, 4
The combination of pertuzumab with trastuzumab reduces recurrence risk and is strongly endorsed by international consensus guidelines for all patients with Stage II or III HER2-positive breast cancer 1, 2

Four cycles of doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide every 21 days, followed by four cycles of a taxane every 21 days with concurrent trastuzumab-pertuzumab, is a traditional backbone that has been the mainstay of neoadjuvant therapy for HER2-positive disease but carries a low risk of secondary acute myeloid leukemia and potential cardiac toxicity 1, 2, 3
Taxane plus carboplatin with concurrent trastuzumab-pertuzumab for 12-18 weeks is an anthracycline-free regimen that demonstrates similar efficacy to anthracycline-containing regimens with improved cardiac safety 1, 2, 3, 5

Total neoadjuvant treatment duration is 12-24 weeks, depending on the selected regimen, as recommended by the American Society of Clinical Oncology and European Society for Medical Oncology 1, 3
Cardiac assessment with left ventricular ejection fraction measurement is mandatory before initiation, during treatment, and following therapy, according to the European Society for Medical Oncology guidelines 2, 3
Continue HER2-targeted therapy to complete a total of 12 months, including neoadjuvant and adjuvant phases combined, as recommended by the American Society of Clinical Oncology and European Society for Medical Oncology 1, 2, 3

If pathological complete response is achieved, continue trastuzumab to complete 12 months total of HER2-directed therapy, as recommended by the American Society of Clinical Oncology and European Society for Medical Oncology 1, 2
If residual disease is present, switch to trastuzumab emtansine for 14 cycles in the adjuvant setting, as this significantly improves invasive disease-free survival compared to continuing trastuzumab alone, based on the KATHERINE trial and European Society for Medical Oncology guidelines 1, 2, 3, 6

Do not use T-DM1 plus pertuzumab as the neoadjuvant regimen, as the KRISTINE study demonstrated significantly lower pathological complete response rates and higher risk of locoregional progression compared to standard taxane-carboplatin-trastuzumab-pertuzumab, according to the European Society for Medical Oncology guidelines 4
Do not omit taxanes from the neoadjuvant regimen, as complete withdrawal of docetaxel or paclitaxel is not recommended as standard practice for HER2-positive patients, according to the American Society of Clinical Oncology and European Society for Medical Oncology guidelines 4
Do not use trastuzumab alone without pertuzumab for Stage IIIA disease, as dual blockade is the established standard for locally advanced HER2-positive breast cancer, according to the American Society of Clinical Oncology and European Society for Medical Oncology guidelines 1, 2, 3